172 related articles for article (PubMed ID: 18644960)
41. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.
Diacon AH; Maritz JS; Venter A; van Helden PD; Andries K; McNeeley DF; Donald PR
Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1561-5. PubMed ID: 20820832
[TBL] [Abstract][Full Text] [Related]
42. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
Namasivayam S; Maiga M; Yuan W; Thovarai V; Costa DL; Mittereder LR; Wipperman MF; Glickman MS; Dzutsev A; Trinchieri G; Sher A
Microbiome; 2017 Jul; 5(1):71. PubMed ID: 28683818
[TBL] [Abstract][Full Text] [Related]
43. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Miyazaki E; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
[TBL] [Abstract][Full Text] [Related]
44. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
Klemens SP; Cynamon MH
Antimicrob Agents Chemother; 1996 Feb; 40(2):298-301. PubMed ID: 8834869
[TBL] [Abstract][Full Text] [Related]
45. [Trends in tuberculosis treatment duration].
Veziris N; Aubry A; Truffot-Pernot C
Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
[TBL] [Abstract][Full Text] [Related]
46. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
47. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
49. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
50. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
Dhillon J; Dickinson JM; Sole K; Mitchison DA
Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
[TBL] [Abstract][Full Text] [Related]
51. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
52. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
53. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
54. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Andries K; Gevers T; Lounis N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
[TBL] [Abstract][Full Text] [Related]
55. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
56. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
57. Present status of chemotherapy for tuberculosis.
Grosset JH
Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
[TBL] [Abstract][Full Text] [Related]
58. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
Moulding TS; Le HQ; Rikleen D; Davidson P
Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145
[TBL] [Abstract][Full Text] [Related]
59. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
60. Moxifloxacin-induced arthropathy.
Wong HY; Chau CH; Yew WW
Int J Tuberc Lung Dis; 2007 Jan; 11(1):117. PubMed ID: 17217142
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
